MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis (MICROPRUNG)
Primary Purpose
Hirschsprung Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Fecal samples
Sponsored by
About this trial
This is an interventional basic science trial for Hirschsprung Disease focused on measuring Hirschsprung Associated EnteroColitis (HAEC)
Eligibility Criteria
Inclusion Criteria:
- Patients from 0 to 16 years ;
- With rectosigmoid Hirschsprung's disease confirmed by rectal biopsies and at surgery;
- Already operated on, whatever the surgical technique was ;
- With a health care insurance;
- Clear information and signed consent form
Exclusion Criteria:
- Long segment Hirschsprung disease ;
- Syndromic Hirschsprung disease ;
- Down syndrome.
Sites / Locations
- Angers University Hospital
- Brest University Hospital
- Caen Univeristy Hospital
- Nantes University Hospital
- Poitiers University Hospital
- Rennes University Hospital
- Tours University Hospital
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Fecal samples
Arm Description
High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
Outcomes
Primary Outcome Measures
Intestinal microbiota composition
Characterize intestinal microbiota in patients with or without HAEC
Secondary Outcome Measures
Full Information
NCT ID
NCT02857205
First Posted
August 2, 2016
Last Updated
September 11, 2018
Sponsor
Rennes University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02857205
Brief Title
MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis
Acronym
MICROPRUNG
Official Title
MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
June 2016 (undefined)
Primary Completion Date
June 2018 (Actual)
Study Completion Date
September 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rennes University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hirschsprung disease is a congenital abnormality due to the lack of migration of neural crest cells in myenteric and submucosal plexi of the bowel wall. The consequence is the absence of parasympathetic control of the distal bowel from the anal sphincter to various levels. The most common type of Hirschsprung disease alters the rectosigmoid (80%). The incidence is around 1/5000 live births. This anomaly requires a surgical ablation of the aganglionic segment.
Regardless of the surgical complications, patients with Hirschsprung disease are exposed to the risk of Hirschsprung Associated EnteroColitis (HAEC). This variable risk, 4-54%, is responsible to a major part of Hirschsprung disease morbimortality. Its onset is more frequent during the first two years of life and then decrease with age.
Its pathogenesis remains unclear but could be due to intestinal homeostasis breakdown that involves microbiota, intestinal barrier, immune system and enteric nervous system. This breakdown of the mutual benefit relation due to microbiota or bowel anomaly is known to be responsible of Crohn's disease onset. Some studies emphasize the role of microbiota in the pathogenesis of HAEC, but the techniques or the methodology with small numbers of patients limit any conclusion or clinical use.
The study hypothesizes microbiota is a major factor in HAEC onset and in their functional bowel problems. Considering HAEC is more frequent the first two years, it's thought that intestinal microbiota changes with time in those patients. This project is innovative because it will use high throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
Multicentre transversal study.
This study has the potential to significantly modify clinical practice for Hirschsprung disease patients: a better care for HAEC and functional troubles thanks to a better understanding of their microbiota, targetted antibiotic treatment for HAEC, prophylactic treatment of patients at high risk of HAEC.
Detailed Description
Primary objective :
Characterize intestinal microbiota in patients with or without HAEC.
Secondary objectives :
Look for a difference in microbiota composition between patients with or without HAEC ;
Study the evolution with age of the microbiota in Hirschsprung disease patients ;
Study predominant taxonomic classification elements in both groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hirschsprung Disease
Keywords
Hirschsprung Associated EnteroColitis (HAEC)
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
118 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fecal samples
Arm Type
Other
Arm Description
High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
Intervention Type
Other
Intervention Name(s)
Fecal samples
Intervention Description
High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
Primary Outcome Measure Information:
Title
Intestinal microbiota composition
Description
Characterize intestinal microbiota in patients with or without HAEC
Time Frame
Sampling day
10. Eligibility
Sex
All
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients from 0 to 16 years ;
With rectosigmoid Hirschsprung's disease confirmed by rectal biopsies and at surgery;
Already operated on, whatever the surgical technique was ;
With a health care insurance;
Clear information and signed consent form
Exclusion Criteria:
Long segment Hirschsprung disease ;
Syndromic Hirschsprung disease ;
Down syndrome.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexis ARNAUD, MD
Organizational Affiliation
Rennes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Angers University Hospital
City
Angers
ZIP/Postal Code
49000
Country
France
Facility Name
Brest University Hospital
City
Brest
ZIP/Postal Code
29000
Country
France
Facility Name
Caen Univeristy Hospital
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Name
Nantes University Hospital
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
Poitiers University Hospital
City
Poitiers
ZIP/Postal Code
86000
Country
France
Facility Name
Rennes University Hospital
City
Rennes
ZIP/Postal Code
35000
Country
France
Facility Name
Tours University Hospital
City
Tours
ZIP/Postal Code
37000
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Case Report Form
Citations:
PubMed Identifier
35847080
Citation
Arnaud AP, Cousin I, Schmitt F, Petit T, Parmentier B, Levard G, Podevin G, Guinot A, DeNapoli S, Hervieux E, Flaum V, De Vries P, Randuineau G, David-Le Gall S, Buffet-Bataillon S, Boudry G. Different Fecal Microbiota in Hirschsprung's Patients With and Without Associated Enterocolitis. Front Microbiol. 2022 Jun 30;13:904758. doi: 10.3389/fmicb.2022.904758. eCollection 2022.
Results Reference
derived
Learn more about this trial
MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis
We'll reach out to this number within 24 hrs